Rating Change
HC Wainwright & Co. reiterated its Buy rating on Pyxis Oncology, Inc. Common Stock (NASDAQ:PYXS) on August 18, 2026.
reiterateNASDAQ:PYXS
HC Wainwright & Co. Reiterates Buy Rating on Pyxis Oncology, Inc. Common Stock (PYXS)
HC Wainwright & Co. reiterated its Buy rating on Pyxis Oncology, Inc.
At publication ·
What changed
Pyxis Oncology, Inc. Common Stock (NASDAQ:PYXS) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $3.01
- Market capitalization
- $274.2M
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Pyxis Oncology (PYXS) on August 18, 2026, with the stock trading at $3.01 and a market capitalization of $274.2 million.
Market Context
Pyxis Oncology, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $3.01 with a market capitalization of $274.2M. The stock has gained 181.3% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Pyxis Oncology, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Pyxis Oncology, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 03, 2026 | Wells Fargo | Overweight | N/A |
| Jul 02, 2026 | Leerink Partners | Outperform | N/A |
| May 05, 2026 | Wedbush | Outperform | N/A |
| Mar 24, 2026 | Stifel | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View PYXS Stock Page
Frequently Asked Questions
What does the Buy rating mean for PYXS?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Pyxis Oncology, Inc. Common Stock (NASDAQ:PYXS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PYXS forecast page.